(Q33636614)

28 July 2017

1 reference

title

Overview of the clinical experience with Neoral in transplantation (English)

1 reference

28 July 2017

Frei U

1

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

Transplantation Proceedings

28 July 2017

published in

1 reference

28 July 2017

volume

31

1 reference

28 July 2017

issue

3

1 reference

28 July 2017

page(s)

1669-1674

1 reference

Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Optimizing the use of cyclosporine in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Malignant tumors in renal transplant patients the scandia transplant material

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Long-term experience with Sandimmun Neoral: results in de novo and stable renal transplant patients after 24-month treatment. The German Neoral Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Renal function following conversion from Sandimmune to Neoral in stable renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

The Swedish nationwide experience of converting transplant patients treated with Sandimmun to the new galenic formulation Sandimmun-neoral. The Swedish Sandimmun-Neoral Conversion Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

UK multicentre study to assess the safety and tolerability of Neoral in stable renal transplant patients. UK Neoral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. The Neoral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: a report of the Canadian Neoral Renal Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Immunosuppression (Neoral vs Sandimmune) in pediatric kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Renal transplantation in African-American recipients: three decades at a single center

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Improved absorption and bioavailability of cyclosporine A from a microemulsion formulation in lung transplant recipients affected with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Comparison of neoral and sandimmun cyclosporines for de novo lung transplantation in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Induction of immunosuppression by microemulsion cyclosporine in liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Risks associated with conversion of stable patients after liver transplantation to the microemulsion formulation of cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Neoral versus Sandimmun in kidney-pancreas transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900090-1

7 January 2021

10.1016/S0041-1345(99)00090-1

Identifiers

DOI

1 reference

28 July 2017

1 reference